Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open Label, Randomized Study to Compare Antiretroviral Therapy (ART) Initiation When CD4 is Between 15% to 24% to ART Initiation When CD4 Falls Below 15% in Children With HIV Infection and Moderate Immune Suppression
Brief Summary: The purpose of this study is to determine when HIV infected children should begin taking anti-HIV medications in order to improve both patient quality of life and survival.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abacavir, Drug: Efavirenz, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nelfinavir, Drug: Nevirapine, Drug: Zidovudine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abacavir, Drug: Efavirenz, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nelfinavir, Drug: Nevirapine, Drug: Zidovudine | Intervention Type: DRUG; Name: Abacavir; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Efavirenz; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Lamivudine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Lopinavir/Ritonavir; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Nelfinavir; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Zidovudine; Assigned to Arm(s): 1, 2
B: Arm Label: Deferred therapy Arm; Type: EXPERIMENTAL; Interventions: Drug: Abacavir sulfate, Drug: Didanosine, Drug: Efavirenz, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nevirapine, Drug: Zidovudine | Arm Label: Early therapy for 40 weeks; Type: EXPERIMENTAL; Interventions: Drug: Abacavir sulfate, Drug: Didanosine, Drug: Efavirenz, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nevirapine, Drug: Zidovudine | Arm Label: Early therapy for 96 weeks; Type: EXPERIMENTAL; Interventions: Drug: Abacavir sulfate, Drug: Didanosine, Drug: Efavirenz, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nevirapine, Drug: Zidovudine | Intervention Type: DRUG; Name: Abacavir sulfate; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks | Intervention Type: DRUG; Name: Didanosine; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks | Intervention Type: DRUG; Name: Efavirenz; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks | Intervention Type: DRUG; Name: Lamivudine; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks | Intervention Type: DRUG; Name: Lopinavir/Ritonavir; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks | Intervention Type: DRUG; Name: Zidovudine; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks
C: Intervention Type: DRUG; Name: nevirapine; Assigned to Arm(s): N/A
D: Arm Label: Coh I: NVP; Type: EXPERIMENTAL; Interventions: Drug: Lamivudine, Drug: Nevirapine, Drug: Zidovudine | Arm Label: Coh I: LPV/r; Type: EXPERIMENTAL; Interventions: Drug: Lamivudine, Drug: Lopinavir/ritonavir, Drug: Zidovudine | Arm Label: Coh II: NVP; Type: EXPERIMENTAL; Interventions: Drug: Lamivudine, Drug: Nevirapine, Drug: Zidovudine | Arm Label: Coh II: LPV/r; Type: EXPERIMENTAL; Interventions: Drug: Lamivudine, Drug: Lopinavir/ritonavir, Drug: Zidovudine | Intervention Type: DRUG; Name: Lamivudine; Assigned to Arm(s): Coh I: LPV/r, Coh I: NVP, Coh II: LPV/r, Coh II: NVP | Intervention Type: DRUG; Name: Lopinavir/ritonavir; Assigned to Arm(s): Coh I: LPV/r, Coh II: LPV/r | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): Coh I: NVP, Coh II: NVP | Intervention Type: DRUG; Name: Zidovudine; Assigned to Arm(s): Coh I: LPV/r, Coh I: NVP, Coh II: LPV/r, Coh II: NVP

Answer: A